Navigation Links
Oppenheimer's Investment Bank Continues Expansion -- Lance Alstodt Named Managing Director - Healthcare
Date:10/7/2009

NEW YORK, Oct. 7 /PRNewswire/ -- Oppenheimer & Co. Inc., a unit of Oppenheimer Holdings, is pleased to announce that Lance Alstodt will join the firm as Managing Director in Healthcare in the firm's burgeoning Investment Banking area. He will report to Brian McCarthy, Oppenheimer's Head of Healthcare Investment & Corporate Banking.

"Lance is an experienced and very capable senior banker in the medical technology space. He will be a real driver of our medical technology effort and is an important addition to the firm," said Brian McCarthy.

Lance joins Oppenheimer from Bank of America Merrill Lynch, where he worked in both the Global Mergers & Acquisitions and Global Healthcare Investment Banking Groups, generating and executing financing and advisory transactions in the Medical Technology sector.

Before moving to Bank of America Merrill Lynch, Lance had worked in the Global Mergers and Acquisitions Group at JP Morgan Chase, with a focus on Healthcare.

"Medical technology is an important piece of our Healthcare investment banking practice and we view Lance as a highly strategic hire and we're delighted he has joined us," said Marshall Heinberg, Oppenheimer's Head of Investment & Corporate Banking.

Oppenheimer & Co. Inc. (Oppenheimer), a principal subsidiary of Oppenheimer Holdings Inc. (OPY on the New York Stock Exchange), provides a full range of wealth management, securities brokerage and investment banking services to high-net-worth individuals, families, corporate executives, local governments, businesses and institutions.

Certain statements in this release may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially, as discussed in the Company's filings with the Securities and Exchange Commission.

SOURCE Oppenheimer & Co. Inc.


'/>"/>
SOURCE Oppenheimer & Co. Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Sequella Receives American Recovery and Reinvestment Funding Through the NIH
2. DOR BioPharma, Inc. Executes $400,000 Equity Investment Agreement With Numoda Corporation
3. The Quigley Corporation Reports Third Quarter Results, Increases Investment in Pharmaceutical R&D for Diabetic Neuropathy
4. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Health Robotics CytoCare(TM) Global Expansion Continues With Grifols International in Latin America
7. Cord Blood America Continues to Reduce Debt; Three Notes Retired
8. Catalyst Pharmaceutical Partners Continues Clinical Development of CPP-109 For The Treatment of Cocaine and Methamphetamine Addiction
9. TMS Health Continues to Expand - Adding Over 60 New Jobs at Boca Raton Headquarters
10. Abbotts XIENCE V(R) Continues to Outperform TAXUS With Sustained Clinical Advantages and Impressive Long-Term Safety Results in SPIRIT III Trial
11. 18 month Follow-up Data on Phase III Study of Pixantrone in Late Stage Relapsed or Refractory, Aggressive Non-Hodgkins Lymphoma Continues to Demonstrate Significant Improvement in Complete Remission and Progression Free Survival Over Standard Chemotherap
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... , Feb. 4, 2016 Worldwide Radiology ... significant growth as next generation systems provide a ... radiology for cancer surgery. New systems pinpoint the ... that has been such a problem previously, limiting ... Radiosurgery robots take cancer surgery far beyond what ...
(Date:2/4/2016)... LONDON , Feb. 4, 2016 ... Summary Global Markets Direct,s, ,Wegener Polyangiitis - ... the Wegener Polyangiitis,s therapeutic pipeline. This report ... Wegener Polyangiitis, complete with comparative analysis at various ... action (MoA), route of administration (RoA) and molecule ...
(Date:2/4/2016)... 2016 Global Immunology Market to 2022 ... long-term market growth Summary Immune-mediated inflammatory ... disorders that affect 5–7% of western populations. Although ... symptoms and key patient demographics, they are pathophysiologically ... and an inappropriate immune response. Generally, disease-modifying anti-rheumatic ...
Breaking Medicine Technology:
(Date:2/6/2016)... ... February 06, 2016 , ... With the FCPX LUT: Summer ... grades to their footage. A LUT is a Lookup Table that contains a mathematical ... color indicated by the table. By manipulating each pixel, LUT's can change each color ...
(Date:2/5/2016)... ... 05, 2016 , ... VeloReality President and co-founder ... LYNX VR Indoor Trainer with multi-rider capability to an enthusiastic audience at the ... reduce the weight of the unit, they also enhance the rider's experience with ...
(Date:2/5/2016)... Santa Rosa, CA (PRWEB) , ... February 05, ... ... are pleased to announce the addition of micro-needling services in their Napa Valley ... appearance. The founders of Plastic Surgery Associates, Dr. Canales and Dr. Furnas, are ...
(Date:2/5/2016)... ... February 05, 2016 , ... US Sports Camps , official operators ... to direct high-performance kids yoga training. ChildLight Yoga Studio is centrally situated in the ... Boston. , ChildLight Yoga Studio founder Lisa Flynn expresses her excitement, “We are thrilled ...
(Date:2/5/2016)... ... February 05, 2016 , ... Boar’s Head Brand®, one of the nation’s ... weekend’s Big Game. Take the stress out of your party preparation – follow these ... at every stage of the game. , “The key to hosting a successful game-day ...
Breaking Medicine News(10 mins):